STAT: psychedelics· Adam Feuerstein·AI score62
Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront
STAT+: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley
AI summary
Eli Lilly is acquiring AtaiBeckley, a developer of psychedelic treatments for mental health conditions.
Key facts
- Organisation
- AtaiBeckley
- Jurisdiction
- United States
- Source
- STAT: psychedelics (statnews.com)
- Published
- Original
- Read it at statnews.com
How this summary was made
The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method
Source: STAT: psychedelics · statnews.com
Connected to
- Organisation
- AtaiBeckley
- Jurisdiction
- United States